Macroaxis: Personalized Investing
Simple Personalized Investing

SP 500   1,655   13.81  Index Moved Down -0.83%
GILD AMGN BIIB CELG Consumption Conservative Analyst Signal Macroaxis 15 
United States GSPC USD ...  |  Investing Themes


Processing
Collecting data for SNTS

Santarus quote and profile

 
 Companies |  Insiders  | Dashboard  
     
22.28
  
STOCK
0.00  No Change   0.00%  
Year To Date
4.8222.3
Last 1 Month(s)
17.7522.3
May 23 2013 

Diversification Suggestion

Use Santarus to protect against small markets fluctuations. The stock experiences normal downward trend, but the immediate impact on correlations cannot be determined at the moment
Analyze Santarus Inc Trend or Check current 30 days Santarus correlation with market (S&P 500)
1 Month Beta 2.82  
Highest Price:  
Lowest Price:  
22.3  
17.75  
May 21 2013 
May 01 2013 
As market goes up, the company is expected to significantly outperform it. However, if the market returns are negative, Santarus will likely underperform.
Santarus Inc Large BetaSantarus Inc Beta Legend
SNTS United States Nasdaq
Santarus Inc
Healthcare
Biotechnology
Benchmark S&P 500
http://www.santarus.com
Contact Number: 858. 314. 5700
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation1.12 B
Shares Outstanding63.91 M
Number of Shares Shorted3.07 M
Revenue217.96 M
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 thisGreen SNTS SNTS agains markets  0.00 % No Change  
 United States SP 500   0.83 % Macroaxis: 0.83 Moved Down  
 
 United States NYSE   0.94 % Macroaxis: 0.94 Moved Down  
 
 United States Russel   1.65 % Macroaxis: change 1.65 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Santarus Leadership

Gerald Proehl CEO and President and Executive Director, MBA
David Hale Independent Chairman of the Board
E Ballard Senior Vice President - Medical Affairs and Pharmacovigilance
Teri Chuppe Vice President Corporate Controller

Santarus Price and Market Media

The median price of Santarus for the period between Tue, Apr 23, 2013 and Thu, May 23, 2013 is 20.2 with a coefficient of variation of 7.71. The daily time series for the period is distributed with a sample standard deviation of 1.54, arithmetic mean of 19.97, and mean deviation of 1.35. The Stock received substential amount of media coverage during this period.
Santarus         SP 500
Price Growth (%)
 
1
The Zacks Analyst Blog Highlights Merck GlaxoSmithKline VIVU...05/01/2013Macroaxis: News
2
Santarus Inc. Tops Q1 EPS by 18c Boosts FY13 Outlook05/07/2013Macroaxis: News
3
Big Gainers Arena Pharmaceuticals Inc. Santarus Inc ...05/09/2013Macroaxis: News
4
Santarus Inc. Is a Real Gas05/22/2013Macroaxis: News

Santarus Summary

Santarus Inc [SNTS] is traded on NASDAQ in USA. It is located in Santarus, Inc.San Diego, CA and employs 290 people. The company currently falls under 'Mid-Cap' category with current market capitalization of 1.2 B. Santarus Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 63.91 M outstanding shares of which 3.07 M shares are at this time shorted by private and institutional investors with about 3.3 trading days to cover.
Santarus, Inc., a specialty biopharmaceutical company, engages in acquiring, developing, and commercializing proprietary solutions that address the needs of patients treated by physician specialists. more
Past Market
Over 30
Days
13
Out Of
100
 
Chance of
Less
Than
%
 
Follow Santarus with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Santarus to your reader
 

Santarus Research Report

Santarus vs. Gilead

Correlation analysis and fundamentals comparison between Santarus Inc and Gilead Sciences

Santarus Executives

Debra Crawford CFO, Principal Accounting Officer, Sr. VP, Secretary and Treasurer

Santarus Directors

Alessandro Cha Director
Michael Herman Independent Director, MBA
Kent Snyder Independent Director, MBA
Daniel Burgess Independent Director, MBA
Ted Love Independent Director

Santarus Fundamentals

Short Ratio vs One Year Low
Net Income vs Current Liabilities
Short Ratio vs Shares Outstanding
Cash Flow from Operations vs Current Liabilities

Santarus vs Competition

Santarus vs. Gilead Sciences Inc
Santarus vs. Amgen Inc
Santarus vs. Biogen Idec Inc
Santarus vs. Celgene Corporation
Santarus vs. Regeneron Pharmaceuticals Inc
Santarus vs. Alexion Pharmaceuticals Inc
Santarus vs. Vertex Pharmaceuticals Incorporated
Santarus vs. BioMarin Pharmaceutical Inc
Santarus vs. Illumina Inc
Santarus vs. Onyx Pharmaceuticals Inc

Santarus May 23 2013 Opportunity Range

Downside Deviation1.85
Information Ratio0.1813
Maximum Drawdown12.9
Value At Risk(2.63)
Potential Upside4.11

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium